iGRO™ is the first Software Medical Device (SMD) that gives evidence-based predictions for the first 12 months of growth hormone (GH) treatment, using pre-treatment data. iGRO™ applies evidence-based, validated and peer-reviewed growth prediction algorithm models, developed using clinical data in the KIGS database, to provide realistic and personalised growth targets — helping pediatric endocrinologists assess and optimise response to growth hormone treatment. The KIGS database (the Pfizer International Growth Database) is the biggest worldwide database on GH therapy, comprising growth data collected over a 25-year period from over 83,000 children who have received growth hormone treatment from 52 countries. SOFTWARE MEDICAL DEVICE
iGRO
CLIENT: PFIZER
iGRO™ helps clinicians treat children with GHD, TS & SGA.
BENEFITS
Optimization of GH dosing in children
Developed using growth prediction algorithms based on 25+ years of study on 83,000+ children treated with GH
Available in several countries across Europe, Middle East, LatAm and Asia